Clinical utility of measurements of free and total prostate-specific antigen (PSA): A review

Prostate

Volumn 29, Issue SUPPL. 7, 1996, Pages 64-69

  Catalona, William J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

detection; free PSA; prostate cancer screening; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CANCER SCREENING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TISSUE DISTRIBUTION; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; REVIEW; TECHNIQUE;

HUMANS; MALE; METHODS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030346620     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1996)7+<64::AID-PROS9>3.0.CO;2-J     Document Type: Conference Paper

References (48)

1. Riegman PH, Vliestra RJ, van der Korput J, Romijn J, Trapman J: Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem Biophys Res Commun 159:95-102, 1989.
2. Lilja H: Significance of different molecular forms of serum PSA: The free, noncomplexed form of PSA versus that complexed to alpha-1-antichymotrypsin. Urol Clin North Am 20:681-686, 1993.
3. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE: Molecular forms of prostate-specific antigen and the kallikrein gene family: A new era. Urology 45:729-744, 1995.
4. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, Valenzuela L, Murphy GP, Chu TM: Prostate antigen: A marker for human prostate epithelial cells. JNCI 48:1229-1232, 1981.
5. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith D, Catalona WJ: Effects of rectal examination, prostatic massage, ultrasonography, and needle biopsy on serum prostate-specific antigen levels. J Urol 147:810-814, 1992.
6. Tchetgen M-B, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE: Ejaculation increases the serum prostate-specific antigen concentration. Urology 47:511-516, 1996.
7. Herschman JD, Smith DS, Catalona WJ: Effect of ejaculation on free and total PSA levels. J Urol 155:423, 1996.
8. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
9. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993.
10. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Southwick PC: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994.
11. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
12. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991.
13. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T: Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37:1618-1625, 1991.
14. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
15. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995.
16. Bangma CH, Kranse R, Blijenberg BG, Schroeder FH: The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 46:773-778, 1995.
17. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46:187-194, 1995.
18. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J: Serum concentrations of prostate specific antigen and its complex with alpha-1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344:1594-1598, 1994.
19. Demura T, Shinohara N, Tanaka M, Enami N, Nonomura K, Koyanagi T: Ratio of free and total prostate specific antigen: A method of detecting prostate cancer in the cases with PSA levels of 10 ng/ml or lower. J Urol 155:368, 1996.
20. Elgamel AA, Cornillie F, Van Poppel H, Van Dorpe JA, Gero E, Haberzetti C, McCabe R, Baert LV: Free/total PSA ratio (F:T) as a single test for detection of significant T1c prostate cancer. J Urol 155:369, 1996.
21. Miller MI, Katz AE, Ikeguchi E, Olsson CA, Benson MC: Patient outcome when free: total (F:T) PSA, PSA density and PSA velocity are utilized to improve serum PSA specificity: A 5 year study. J Urol 155:369, 1996.
22. Reissigl A, Klocker H, Pointer J, Ennemoser O, Fink K, Bartsch G: Improvement of prostate cancer (PCA) screening by determination of the ratio free/total (f/t) PSA in addition to PSA levels. A prospective study. J Urol 155:370, 1996.
23. Oesterling JE, Wojno KJ, England B, Vessella RL, Lange PH, Noteboom J, Wright GL, Schellhammer PF, Weigand RA, Oison RM, Dowell DL: A comparison of free to total PSA (F/T) ratio to total PSA for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer (CaP) using the Abbott AxSYM system. J Urol 155:370, 1996.
24. Saito S, Ozu C, Nakamura K, Tachibana M, Baba S, Ishibashi M, Ohtake T, Kano S, Murai M: Screening of prostate cancer with free and total prostate specific antigen (PSA) ratio. J Urol 155:373, 1996.
25. Partin AW, Subong ENP, Kelley CA, Hortopan S, Carter HB, Chan DW, Walsh PC, Rittenhouse HG, Wolfert RL, Gasior GH, Southwick P: Prospective analysis of free PSA to total PSA ratio (PSAf/PSAt) for prostate cancer detection and the clearance rate of PSAf after radical prostatectomy. J Urol 155:416, 1996.
26. Sagalowsky AI, Wiams FH, Jialal I, Roehrborn CG: Ability of the ratio between free and total prostate specific antigen (PSA) and different PSA assays to predict ultimate histological diagnosis of prostate tissue. J Urol 155:420, 1996.
27. Yemoto CM, Nolley R, Prestigiacomo AF, Stamey TA: Free (f) and total (t) PSA density in patients with prostate cancer (CaP) and benign prostatic hyperplasia (BPH). J Urol 155:374, 1996.
28. Bianchi GD, Maynard M, Williams RD: Differentiation of prostatitis from prostate cancer using ratio of free to total PSA. J Urol 155:425, 1996.
29. Morgan TO, McLeod DG, Moul JW, Connelly RR, Douglas TH, Murphy GP: Clinical use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. J Urol 155:370, 1996.
30. Chen Y-T, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF: Using proportions of free to total prostate-specific antigen, age and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47:518-524, 1996.
31. Marley GM, Patton KP, Miller MC, Zhao G, Veltri RW, Kattan MW, Wright GR, Schellhammer PF, Vessella RL: Free/total prostate specific antigen (PSA) serum ratio predicts probability of cancer diagnosis in patients with elevated total PSA. J Urol 155:422, 1996.
32. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ: Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 155:415, 1996.
33. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289-294, 1995.
34. Smith DS, Catalona WJ, Herschman JD: Longitudinal screening for prostate cancer with prostate-specific antigen: Implications for population trends. JAMA (in press).
35. Catalona WJ, Colberg JW, Smith DS, Ornstein DK, Shayka JJ: Measurement of percent-free PSA improves specificity for lower PSA cutoffs in prostate cancer screening. J Urol 155:422, 1996.
36. Smith DS, Catalona WJ, Bullock AD: Operating characteristics of prostate cancer screening tests in African-American and white men. J Urol 155:376, 1996.
37. Carter HB, Pearson JD, Metter J, Chan DW, Andres R, Fozard JL, Rosener W, Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
38. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20:653-663, 1993.
39. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993.
40. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152:1163-1167, 1994.
41. Catalona WJ, Richie JP, de Kernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2031-2036, 1994.
42. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristics curves. J Urol 152:2037-2042, 1994.
43. Smith DS, Catalona WJ, Keetch DW: Comparison of percent free PSA and PSA density as methods to enhance the specificity of PSA screening. J Urol 155:422, 1996.
44. Oesterling JE, Jacobsen SJ, Klee GG, Petterson K, Piironen T, Abrahamson PA, Stenman UH, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate specific antigen: The established of appropriate reference ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995.
45. Graefen M, Hammerer P, Henke P, Hitz H, Huland E, Huland H: Percentage of free PSA does not correlate with pathological outcome. J Urol 155:370, 1996.
46. Partin AW, Subond ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, Luderer AA: Free/ total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer. J Urol 155:415, 1996.
47. Lerner SE, Jacobsen SJ, Bergstralh EJ, Klee GG, Blute ML, Lieber MM, Zincke H, Lilja H, Oesterling JE: Free, complexed, and total serum PSA concentrations and their proportions in predicting stage, grade, and DNA ploidy in patients with prostate cancer (PC). J Urol 155: 416, 1996.
48. Hendricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J Urol 155:369, 1996.